$RARE

[Form 4] Ultragenyx Pharmaceutical Inc. Insider Trading Activity

This article details an insider trading activity at Ultragenyx Pharmaceutical Inc. (RARE), specifically a Form 4 filing by director Daniel G. Welch. Welch reported receiving 7,751 shares of common stock as restricted stock units and a stock option for 14,058 shares, with both vesting fully by the company's next Annual Meeting of Stockholders or May 14, 2027. The filing indicates a neutral impact and sentiment regarding these transactions.

Original reporting
Published May 18, 2026, 10:23 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 18, 2026, 11:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$RARE
Neutral
medium confidence
Mentioned
$RARE
alphai data visualization · based on Stock Titan
Decision brief

The 30-second read

$RARENeutralLow
01

Why it matters

The recent insider transaction is routine and does not signal significant upcoming changes or catalysts.

02

Market read

Insider trading activity at RARE has limited immediate market impact and is considered neutral for trading decisions.

03

What to watch

The insider's transaction is routine and does not indicate material positive or negative developments; broader market conditions should be considered.

Timing: low

Background

Ultragenyx Pharmaceutical Inc. (RARE) is a biotechnology company focused on rare genetic diseases.

Company-level read

Ticker impact

$RARENeutralMedium confidence
Context

Insider trading activity at Ultragenyx Pharmaceutical Inc. (RARE) involving director Daniel G. Welch's recent Form 4 filing.

Expected impact

Minimal to no short-term price movement expected.

Evidence & confidence

The insider acquired shares through restricted stock units and stock options, both fully vesting by May 14, 2027, suggesting confidence in long-term prospects rather than short-term trading signals.

Market effects

Limited sector impact; insider activity is company-specific and does not suggest sector-wide changes.

Minimal regional influence; activity is localized to company insiders.

Negligible; insider trading at a single biotech firm has limited global market implications.

Counterpoint

Some may interpret insider holdings as confidence in the company's long-term growth, potentially supporting a buy-and-hold strategy.

Key entities

  • Daniel G. Welch

    A director at Ultragenyx Pharmaceutical involved in the recent Form 4 filing.

  • Ultragenyx Pharmaceutical Inc.

    Biotech company specializing in rare genetic diseases.

Related articles

$RAREMed

Ultragenyx Pharmaceutical Q2 Earnings Call Highlights

Ultragenyx Pharmaceutical (NASDAQ:RARE) reaffirmed revenue and 2026 combined R&D and SG&A guidance, expecting flat to down low single digits from 2025, and at least a 15% decline in 2027. In Q2, Crysvita patient starts rose in Latin America and Turkey, and DOJOLVI had about 675 reimbursed patients in North America. FDA PDUFA dates are Aug. 23 for DTX-401 and Sept. 19 for UX-111.

$ACIMed

Albertsons recalls ready-to-eat items in multiple states amid salmonella-linked jalapeño investigation

Albertsons Companies said it is voluntarily recalling four ready-to-eat products containing jalapeños supplied by Taylor Farms, including items sold at Randalls in Texas. The recall followed a supplier recall tied to an ongoing federal investigation and an FDA probe of a Salmonella Javiana outbreak. FDA reported 345 illnesses in 27 states, 36 hospitalizations, no deaths.

$CMGMed

Salmonella outbreak from Mexican jalapeños reported in 27 U.S. states

U.S. health authorities are investigating a Salmonella outbreak linked to Mexican jalapeño peppers. The CDC and FDA say 345 people are ill across 27 states, with 36 hospitalizations and no deaths. The supplier, Coast Citrus Distributors, recalled peppers sent to restaurants including Chipotle and QDOBA. Chipotle removed jalapeños from some outlets and shares fell over 8% on Aug. 4.